Imatinib mesylate is a selective protein kinase inhibitor, currently
used mainly for the treatment of malignancies like chronic myeloid leukemia
(CML) and gastrointestinal stromal tumors (GISTs). The side-effect profile of
this drug includes fluid retention, muscle cramps, diarrhoea, myelosuppression
and skin rashes. Cutaneous toxicity has been reported in 18 to 69% of patients
with GIST treated with doses ranging from 400 to 800mg once a day. Of these,
maculo-papular eruptions and oedema developed most commonly. Herein we report a
case of GIST who developed features of drug rash with eosinophilia and systemic
symptoms (DRESS) on initiation of imatinib.see more
No comments:
Post a Comment